|
Comparison of clinical and laboratory parameters of COVID-19 in diabetic patients using different glucose-lowering drugs: a retrospective study
|
S Rostami-Mansoor *   , S Khafri , S F Jalali , F Mohdenipoor , H Parsian , M Bayani |
| Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran , srostami.m@gmail.com |
|
|
Abstract: (890 Views) |
Background and Objective: Diabetes is a common metabolic disease that increases the risk of mortality of COVID-19. This study was done to compare the clinical characteristics and laboratory parameters of COVID-19 in diabetic patients using different glucose-lowering drugs to find out the proper predictors of disease severity.
Methods: 157 diabetic patients with confirmed COVID-19 were enrolled in three groups according to the antidiabetic medications used before admission (metformin, insulin and sulfonylurea).
Findings: In 157 diabetic patients, the hospitalization length in the metformin group was lower than the no metformin group while duration of hospitalization and critical form of the disease in the insulin group were higher than the no insulin group. Furthermore, the levels of blood sugar, BUN, ALT and WBC were lower in the metformin group while ALP, ALT, BUN and creatinine levels were significantly higher in insulin group. In sulfonylurea group the levels of BUN and ALT were lower compared to the no sulfonylurea group. We also found that BUN and total bilirubin were the proper parameters to predict COVID-19 severity and mortality in metformin and insulin group respectively.
Conclusion: It seems that the outcomes of renal function test, bilirubin and O2 saturation are important parameters to predict COVID-19 severity in diabetic patients using different antidiabetic medications.
|
|
| Keywords: COVID-19, diabetes, glucose- lowering drugs, laboratory parameters. |
|
|
Full-Text [PDF 1320 kb]
(738 Downloads)
|
Type of Study: Original Article |
Subject:
بیوشیمی
Received: 2022/12/26 | Accepted: 2022/12/28 | Published: 2023/01/28
|
|
|
|
|
|
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
